These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 16140073)
1. Cytokeratin-20 immunocytology in voided urine exhibits greater sensitivity and reliability than standard cytology in the diagnosis of transitional cell carcinoma of the bladder. Melissourgos ND; Kastrinakis NG; Skolarikos A; Pappa M; Vassilakis G; Gorgoulis VG; Salla C Urology; 2005 Sep; 66(3):536-41. PubMed ID: 16140073 [TBL] [Abstract][Full Text] [Related]
2. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921 [TBL] [Abstract][Full Text] [Related]
3. Voided urinary cytology in bladder cancer: is it time to review the indications? Talwar R; Sinha T; Karan SC; Doddamani D; Sandhu A; Sethi GS; Srivastava A; Narang V; Agarwal A; Adhlakha N Urology; 2007 Aug; 70(2):267-71. PubMed ID: 17826487 [TBL] [Abstract][Full Text] [Related]
4. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder. Degtyar P; Neulander E; Zirkin H; Yusim I; Douvdevani A; Mermershtain W; Kaneti J; Manor E Urology; 2004 Feb; 63(2):398-401. PubMed ID: 14972510 [TBL] [Abstract][Full Text] [Related]
5. Immunostaining of cytokeratin 20 in cells from voided urine for detection of bladder cancer. Golijanin D; Shapiro A; Pode D J Urol; 2000 Dec; 164(6):1922-5. PubMed ID: 11061882 [TBL] [Abstract][Full Text] [Related]
6. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction. Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962 [TBL] [Abstract][Full Text] [Related]
7. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma. Klein A; Zemer R; Buchumensky V; Klaper R; Nissenkorn I Cancer; 1998 Jan; 82(2):349-54. PubMed ID: 9445193 [TBL] [Abstract][Full Text] [Related]
8. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813 [TBL] [Abstract][Full Text] [Related]
9. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder. Jamshidian H; Kor K; Djalali M Urol J; 2008; 5(4):243-7. PubMed ID: 19101898 [TBL] [Abstract][Full Text] [Related]
10. Value of reverse transcription polymerase chain assay in peripheral blood of patients with urothelial cancer. Okegawa T; Kinjo M; Nutahara K; Higashihara E J Urol; 2004 Apr; 171(4):1461-6. PubMed ID: 15017198 [TBL] [Abstract][Full Text] [Related]
11. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma. Hakenberg OW; Fuessel S; Richter K; Froehner M; Oehlschlaeger S; Rathert P; Meye A; Wirth MP Urology; 2004 Dec; 64(6):1121-6. PubMed ID: 15596183 [TBL] [Abstract][Full Text] [Related]
12. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Kumar A; Kumar R; Gupta NP Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358 [TBL] [Abstract][Full Text] [Related]
13. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer. Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669 [TBL] [Abstract][Full Text] [Related]
14. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562 [TBL] [Abstract][Full Text] [Related]
15. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment. Bartoletti R; Dal Canto M; Cai T; Piazzini M; Travaglini F; Gavazzi A; Rizzo M Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429 [TBL] [Abstract][Full Text] [Related]
16. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675 [TBL] [Abstract][Full Text] [Related]
17. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. Shariat SF; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Sawczuk I; Serretta V; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Wians F; Roehrborn CG; Lotan Y; Perrotte P; Benayoun S; Marberger MJ; Karakiewicz PI J Urol; 2005 May; 173(5):1518-25. PubMed ID: 15821471 [TBL] [Abstract][Full Text] [Related]